Eikon Therapeutics Files for IPO to Fund Cancer Drug Pipeline

Eikon Therapeutics, a cancer drug startup that has raised more than $1 billion in private funding since 2019, filed paperwork on Friday to go public.

The company, run by former Merck & Co. research chief Roger Perlmutter and one-time Merck clinical development leader Roy Baynes, will use the IPO proceeds to advance a group of experimental medicines for cancer and neurological diseases. Four drugs are already in human testing, according to Eikon's IPO filing.

The most advanced asset, EIK1001, is in a Phase 2/3 trial in advanced melanoma and a mid-stage study in lung cancer. An interim analysis is expected later this year.

Who is behind Eikon?

Eikon was formed in 2019 around a Nobel Prize-winning technology that helps scientists examine how proteins move inside cells. But the company built its pipeline through dealmaking rather than discovery alone.

• EIK1001, which targets a pair of toll-like receptors, was licensed from Seven and Eight Biopharmaceuticals.
• EIK1003 and EIK1004, two PARP inhibitors, came from a deal with Impact Therapeutics.
• Eikon's next two cancer prospects were discovered internally and are nearing or just beginning human testing.

Eikon's pitch to investors, as laid out in its filing, revolves around an unproven discovery platform to unearth novel medicines and the ability of a seasoned management team to "opportunistically in-license promising assets."

What makes the drugs different?

Eikon claims EIK1001 can be administered systemically rather than injected directly into a tumor, unlike earlier drugs that targeted toll-like receptor proteins. That difference should enable the drug to spur a stronger immune response, the company said in its filing.

The two PARP inhibitors, EIK1003 and EIK1004, are designed to be more selective than available therapies such as AstraZeneca and Merck's Lynparza. Greater selectivity could help patients avoid hematological side effects like anemia that prompt people to stop treatment. Eikon's drugs may also work alongside chemotherapy — a combination strategy other PARP drugs have struggled with. Dose escalation work for both should be complete later this year, Eikon said.

Eikon's internally discovered programs target "MSI high" tumors, which carry many DNA mutations, and a next-generation version of the androgen receptor antagonists often used against hormone-sensitive tumors like prostate cancer.

Why is the IPO timing significant?

The filing lands at a potential turning point for biotech financings. After more than 100 drug companies went public in 2021, the market entered a prolonged slump. In 2025, only 11 companies raised about $1.6 billion in IPO funding — sector lows since at least 2018, according to BioPharma Dive data.

Conditions improved through 2025. Dealmaking surged, fears about drug pricing policies and tariffs dissipated, venture funding skyrocketed, and most companies that went public ended the year trading above their debut prices.

Those signs suggest "the IPO window in 2026 may begin to reopen," analysts with RBC Capital Markets wrote in a note to clients last week.

Eikon follows the year's first offering from radiopharmaceutical drugmaker Aktis Oncology, which was also one of the largest biotech IPOs since the start of 2024. Eikon's pitch differs from Aktis's, betting on a Nobel-winning science platform plus the licensing instincts of executives who ran Merck's research engine.

The interim readout for EIK1001 in melanoma, expected later this year, will give public investors an early test of whether that bet is justified.